FMO4

Across TCGA pan-cancer cohorts, FMO4 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FMO4 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FMO4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FMO4 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LUAD, LSCC, and CCRCC are the cancer types where FMO4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.406	0.899	.006	12	view →
LSCC	DFS	Median	III,IV	1.000	0.440	.010	10	view →
CCRCC	DFS	Tertile	IV	0.108	0.758	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

FMO4–LUAD (DFS)

Open the LUAD breakdown →